Bellolio Enrique, Pineda Viviana, Burgos María Eugenia, Iriarte M José, Becker Renato, Araya Juan Carlos, Villaseca Miguel, Mardones Noldy
Rev Med Chil. 2015 Dec;143(12):1533-8. doi: 10.4067/S0034-98872015001200005.
To validate the BIRADS in mammography, the calculation of its predictive value in each center is required, as recommended by the American College of Radiology.
To determine the predictive value of the BIRADS system in our center.
All ultrasound guided needle percutaneous biopsies, performed at our center between 2006 and 2010 were reviewed. Predictive value, sensitivity, specificity and diagnostic accuracy of BIRADS were calculated, with a confidence interval of 95%.
Of 1,313 biopsies available, 1,058 met the inclusion criteria. Fifty eight percent of biopsies were performed to women with mammographies classified as BIRADS 4 or 5. The presence of cancer in mammographies classified as BIRADS 0 was 4%. The prevalence of cancer for mammographies BIRADS 1, 2, 3, 4 and 5 were 0, 3, 2.7, 17.7 and 72.4% respectively. The positive and negative predictive values of BIRADS classification were 55 and 92 % respectively.
In our institution BIRADS classification 4 and 5 has a high positive predictive value for detecting cancer as in developed countries.
为验证乳腺钼靶检查中的美国放射学会（ACR）乳腺影像报告和数据系统（BIRADS），需要按照ACR的建议计算其在各中心的预测值。
确定BIRADS系统在我们中心的预测值。
回顾了2006年至2010年在我们中心进行的所有超声引导下经皮穿刺活检。计算了BIRADS的预测值、敏感性、特异性和诊断准确性，置信区间为95%。
在1313例可用活检中，1058例符合纳入标准。58%的活检是针对乳腺钼靶检查分类为BIRADS 4或5的女性进行的。乳腺钼靶检查分类为BIRADS 0的癌症发生率为4%。BIRADS 1、2、3、4和5的乳腺钼靶检查癌症患病率分别为0、3、2.7、17.7和72.4%。BIRADS分类的阳性和阴性预测值分别为55%和92%。
在我们机构中，与发达国家一样，BIRADS分类4和5对检测癌症具有较高的阳性预测值。
